SCHEDULE: FMR LLC Discloses 5.1% Stake in Mineralys Therapeutics

FMR LLC, through its subsidiaries, has reported beneficial ownership of 5.1% of Mineralys Therapeutics Inc.'s common stock as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson, through various entities, have collectively reported beneficial ownership of 4,461,689.46 shares of Mineralys Therapeutics Inc. common stock.
• This ownership stake represents 5.1% of the total outstanding common stock.
• The filing is an amendment to a previous Schedule 13G, indicating a change or update in beneficial ownership.
• The reporting entities include FMR LLC, FIAM LLC, Fidelity Management & Research Company LLC, and Strategic Advisers LLC.
• Abigail P. Johnson is identified as a Director, Chairman, and CEO of FMR LLC, and members of the Johnson family are predominant owners of FMR LLC.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a significant but not controlling stake by a major institutional investor, with no immediate negative implications.

Positives

• Acquisition of a significant stake (5.1%) by a major institutional investor (FMR LLC) suggests confidence in the company's prospects.
• The filing indicates that FMR LLC and its affiliates are active investors in the market.

Negatives

• The filing does not contain any negative financial or operational information about Mineralys Therapeutics Inc. itself, as it is a disclosure of ownership by an external entity.

Risks

• Potential for future stock sales by FMR LLC, which could impact share price.
• Changes in FMR LLC's investment strategy could lead to divestment.

Future Outlook

The filing itself does not provide a future outlook for Mineralys Therapeutics Inc. It is a disclosure of beneficial ownership by FMR LLC.

Management Comments

• FMR LLC and Abigail P. Johnson, through various entities, have collectively reported beneficial ownership of 4,461,689.46 shares of Mineralys Therapeutics Inc. common stock, representing 5.1% of the total outstanding common stock.
• Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC.
• The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares.

Industry Context

StockSavvy.ai notes that the acquisition of a significant stake by a large asset manager like FMR LLC in a biotechnology or therapeutics company is common, reflecting active portfolio management and investment in companies with potential for growth.

Comparison to Industry Standards

• FMR LLC is a major global investment management firm, managing trillions of dollars in assets across various funds and strategies.
• A 5.1% stake in a publicly traded company is a substantial investment, often indicative of a long-term perspective or a significant position within a specific sector fund.
• The filing is a standard Schedule 13G, used by passive investors who acquire more than 5% of a company's stock. This is a common reporting requirement for institutional investors.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the increased institutional ownership positively, potentially leading to increased liquidity and market interest. However, future selling by FMR LLC could pressure the stock price.
• Management of Mineralys Therapeutics Inc.: May see FMR LLC as a stable, long-term shareholder, but will also be aware of the potential for influence or future changes in ownership.
• Competitors: The filing itself has no direct impact on competitors.

Next Steps

• Monitoring of FMR LLC's future trading activity in Mineralys Therapeutics Inc. stock.
• Continued observation of Mineralys Therapeutics Inc.'s operational and financial performance.

Key Dates

Keywords

Mineralys Therapeutics, FMR LLC, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Management